Progenesis

Progenesis focuses on developing and providing genetic testing and counseling, as well as sequencing in the field of next-generation IVF. Progenesis is the first company in the United States to introduce next-generation sequencing (NGS) for pre-implantation genetic testing for aneuploidy (PGT-A) and pre-implantation genetic testing for monogenic diseases (PGT-M). The company offers a range of products for patients at all stages of family planning. All services provided by the company are meticulously designed with the patient in mind, while keeping up with the latest trends in genetics and technology. The company’s carrier screening portfolio is the most comprehensive test available on the market today. We offer embryo screening for many common diseases, including cystic fibrosis, fragile X syndrome, sickle cell disease, and Tay-Sachs disease. The company has introduced the most accurate 24-chromosome aneuploidy screening and monogenic disease testing in the field of IVF.